Shares of Abbott Laboratories (NYSE:ABT) ended Wednesday session in red amid volatile trading. The shares closed down -0.26 points or -0.62% at $41.90 with 11.06 million shares getting traded. Post opening the session at $42.15, the shares hit an intraday low of $41.77 and an intraday high of $42.29 and the price vacillated in this range throughout the day. The company has a market cap of $61.70 billion and the numbers of outstanding shares have been calculated to be 1.47 billion shares.
Abbott Laboratories (ABT) on Aug. 2, 2016 announced the introduction of Alinity™, its harmonized family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment.
Diagnostic testing guides 70 percent of health care decisions. Global testing volumes are rising due to an aging population, the growing management of chronic diseases and increased access to care. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs. Many institutions and labs use multiple diagnostic platforms, often within a larger health care network. As they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximize testing efficiencies and help better manage resources.
Designed with universal, intuitive interfaces as well as common software and hardware, Abbott’s Alinity systems will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster and minimize human errors. By offering a comprehensive solution that addresses the challenges of using multiple diagnostics platforms, while continuing to provide quality results that positively impact patient care, Alinity could potentially change the industry’s testing paradigm.
“Abbott’s Alinity portfolio is unprecedented in the industry,” said Brian Blaser, executive vice president, Diagnostics Products, Abbott. “With our unified family of testing instruments, we’ll be able to offer more efficiency, flexibility and confidence to health systems and better help doctors and nurses get the results they need to improve decision-making and patient care.”
Shares of Biostar Pharmaceuticals Inc (NASDAQ:BSPM) ended Wednesday session in red amid volatile trading. The shares closed down -0.02 points or -0.94% at $2.11 with 95,807.00 shares getting traded. Post opening the session at $2.17, the shares hit an intraday low of $2.11 and an intraday high of $2.35 and the price vacillated in this range throughout the day. The company has a market cap of $4.56 million and the numbers of outstanding shares have been calculated to be 2.21 million shares.
Biostar Pharmaceuticals Inc (BSPM) on Aug. 22, 2016 announced its financial results for the second quarter ended June 30, 2016.
During the fiscal second quarter of 2016, the Company recognized:
- Net sales of $0.6 million, a decrease of approximately $13.6 million, or 95.6% as compared to the same period in 2015.
- Gross profit decreased by approximately $5.6 million, or 95.0% for the three months ended June 30, 2016 as compared to the same period in 2015.
- Sales of Shaanxi Weinan Products increased by approximately $0.4 million, or 302.9% as compared to the same period in 2015.
- Sales and Production of Aoxing Pharmaceutical Products remained temporarily suspended as the Company still working toward renewal of its GMP certificates.
- The Company recorded a provision for doubtful accounts in the amount of $6.3 million during the second quarter. Our results of operations were materially affected by this provision.
- Net loss of $6.9 million as compared to net loss of $0.5 million for the second quarter 2015.